Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Kevin McCullochSEE REMARKS | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 09/28 | 09/29 | 25,000 sh | $10.00 | $250,000 | −1.5% |
John JohnsonDirector | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 06/04 | 06/05 | 15,000 sh | $6.09 | $91,350 | −2.1% |
Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 06/04 | 06/05 | 16,000 sh | $6.09 | $97,440 | −11.2% | |
Dawn HalkuffDirector | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 06/04 | 06/05 | 20,000 sh | $6.09 | $121,800 | −17.4% |
Marla PerskyDirector | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 06/03 | 06/05 | 15,500 sh | $5.90 | $91,450 | −10.9% |
Beth HechtSEE REMARKS | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 06/01 | 06/02 | 16,667 sh | $6.06 | $101,002.02 | −1.4% |
Beth HechtSEE REMARKS | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 05/01 | 05/01 | 16,667 sh | $6.23 | $103,835.41 | −1.4% |
Beth HechtSEE REMARKS | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 04/01 | 04/03 | 16,667 sh | $5.99 | $99,835.33 | −1.4% |
James Aloysius BradyDirector | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 03/30 | 04/01 | 10,834 sh | $5.54 | $60,020.36 | −10.8% |
Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 03/02 | 03/04 | 16,667 sh2 trades | $6.24avg. | $104,084.08 | −1.3% | |
Beth HechtSEE REMARKS | Xeris Biopharma HoldingsXERS | Open-market sale | 02/02 | 02/02 | 16,667 sh | $7.45 | $124,169.15 | −1.3% |
Kevin McCullochSEE REMARKS | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 01/08 | 01/09 | 15,000 sh | $8.00 | $120,000 | −0.9% |
John Patrick Shannon Jr.SEE REMARKS | Xeris Biopharma HoldingsXERS | Open-market sale | 01/05 | 01/06 | 24,907 sh | $7.08 | $176,341.56 | −0.9% |
Beth HechtSEE REMARKS | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 01/02 | 01/05 | 16,667 sh | $7.43 | $123,835.81 | −1.3% |
John JohnsonDirector | Xeris Biopharma HoldingsXERS | Open-market sale | 25/12/19 | 25/12/19 | 135,400 sh | $7.22 | $977,588 | −16.2% |
Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 25/12/12 | 25/12/15 | 15,000 sh | $7.09 | $106,350 | −9.5% | |
Beth HechtSEE REMARKS | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 25/12/01 | 25/12/02 | 16,667 sh | $7.01 | $116,835.67 | −1.2% |
John Patrick Shannon Jr.SEE REMARKS | Xeris Biopharma HoldingsXERS | Open-market sale | 25/11/13 | 25/11/17 | 23,242 sh | $7.46 | $173,385.32 | −0.9% |
Beth HechtSEE REMARKS | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 25/11/11 | 25/11/13 | 16,667 sh | $7.40 | $123,335.8 | −1.2% |
Marla PerskyDirector | Xeris Biopharma HoldingsXERS | Open-market sale10b5-1 plan | 25/09/11 | 25/09/12 | 15,500 sh | $7.72 | $119,660 | −9.8% |